Pliant Therapeutics' stock plummeted, but Kevin Tang’s stake raises takeover hopes. Find out why PLRX stock’s cash reserves ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...

Moving at a rapid-fire clip, Donald Trump has been concentrating power in his hands, pushing the bounds of executive ...

Pliant Therapeutics, Inc.’s PLRX share price has dipped by 10.89%, which has investors questioning if this is right time to ...

I have credible information that some foreign journalists have been approached to publish positive stories of post-Hasina ...

The best softside luggage is flexible and forgiving, often providing extra packing space. After rigorous testing, our editors ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Shares of Pliant Therapeutics PLRX have plunged 88.5% in the past three months following recent setbacks in the clinical development program of its lead product candidate, bexotegrast (PLN-74809), for ...

The president promises 25% tariffs on all imported cars and country-by-country “reciprocal” tariffs based on how much his ...

Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If ...